Sutro Biopharma, Inc.
STRO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.16 | -0.52 | -0.11 |
| FCF Yield | -5.22% | -7.42% | -12.76% | -4.79% |
| EV / EBITDA | -15.45 | 707.22 | -10.01 | -25.74 |
| Quality | ||||
| ROIC | -33.25% | -1.70% | -34.93% | -25.67% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.67 | 3.89 | 0.89 | 0.99 |
| Growth | ||||
| Revenue 3-Year CAGR | 29.50% | 22.48% | -3.77% | -2.90% |
| Free Cash Flow Growth | 14.22% | 35.11% | 5.15% | -11.42% |
| Safety | ||||
| Net Debt / EBITDA | 1.08 | 144.93 | 1.86 | -0.23 |
| Interest Coverage | -4.66 | -0.35 | -6.44 | -7.51 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 36.42 | 11.29 | 70.15 | 52.36 |